Research programme: Crohn's disease therapeutics - DBV Technologies/Icahn School of Medicine

Drug Profile

Research programme: Crohn's disease therapeutics - DBV Technologies/Icahn School of Medicine

Alternative Names: Crohn's disease therapy - DBV Technologies/Icahn School of Medicine

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator DBV Technologies; Icahn School of Medicine at Mount Sinai
  • Developer DBV Technologies
  • Class Proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Crohn's disease

Most Recent Events

  • 13 Jun 2016 Pharmacodynamics data from a preclinical study released by DBV Technologies
  • 18 Feb 2014 Preclinical trials in Crohn's disease in France (Transdermal)
  • 18 Feb 2014 DBV Technologies and Icahn School of Medicine at Mount Sinai agree to co-develop an epicutaneous immunotherapy in France for Crohn's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top